Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results af…

The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported ...
Banyan Hill PublishingOpinion

Chart of the Week: The Calm Before the Margin Call

When investors borrow more to buy stocks, it often means they’re feeling confident. Is today's confidence justified or is it ...

VIZSLA COPPER ANNOUNCES THE ACQUISITION OF THE PALMER CRITICAL MINERALS VMS PROJECT IN ALASKA AND UP TO $25 MILLION NON-BROKERED PR…

Vizsla Copper Corp. (TSX.V: VCU, OTCQB: VCUFF) ("Vizsla Copper" or the "Company") is pleased to announce that it has entered ...